Clinical Trial: Phase III Clinical Study on the Efficacy and Safety of Semaglutide and Ozempic(R) in Patients With Type 2 Diabetes

U.S., July 2 -- ClinicalTrials.gov registry received information related to the study (NCT07046273) titled 'Phase III Clinical Study on the Efficacy and Safety of Semaglutide and Ozempic(R) in Patients With Type 2 Diabetes' on June 23.

Brief Summary: This study is a multicenter, randomized, open, parallel-controlled, Phase III clinical study aimed to evaluate the efficacy and safety of semaglutide injection and Ozempic(R) in patients with type 2 diabetes.

Study Start Date: Aug. 01

Study Type: INTERVENTIONAL

Condition: Type 2 Diabetes (T2DM)

Intervention: DRUG: F027

The starting dose is 0.25 mg once weekly. After 4 weeks the dose should be increased to 0.5 mg once weekly. After at least 4 weeks with a dose of 0.5 mg once weekly, the ...